Home
/ ASTA
/ Competitors

ASTA Competitors and Similar CompaniesClear all

ASTA's competitors and similar companies include Artron Laboratories, North American Rescue, TaiDoc Technology and Roche Farma España.

	ASTA ASTA ((주)아스타) is a company that develops and manufactures medical diagnostic solutions.	Artron Laboratories Artron Laboratories is a company that manufactures medical devices.	North American Rescue North American Rescue (NAR) is a company that manufactures lifesaving medical solutions.	TaiDoc Technology TaiDoc Technology is a company that designs and manufactures medical devices and healthcare products.	Roche Farma España Roche Farma is a pharmaceutical company that manufactures medicines and diagnostic products.
Founding Date	Founding Date 2006	Founding Date 2002	Founding Date 1996	Founding Date 1998	Founding Date 1896
Type	Type Public	Type Private	Type Subsidiary	Type Public	Type Private
Tags	Tags Manufacturing & Industrial medical devices medical diagnostics medtech	Tags Manufacturing & Industrial medical devices medical diagnostics	Tags Manufacturing & Industrial medical devices medical diagnostics	Tags Manufacturing & Industrial medical devices medical diagnostics	Tags Manufacturing & Industrial medical devices medical diagnostics
Locations	Locations Suwon, KR HQ	Locations Burnaby, CA HQ	Locations Greer, US HQ	Locations TW HQ	Locations Madrid, ES HQ Madrid, ES Sant Cugat Del Vallès, ES
Employees	Employees 294% increase	Employees 432% increase	Employees 1531% increase	Employees N/A	Employees 4411% increase
Financial
Revenue (est.)	Revenue (est.) ₩2.6b (FY, 2025)	Revenue (est.) N/A	Revenue (est.) N/A	Revenue (est.) NT$4.2b (FY, 2025)	Revenue (est.) N/A
Cost of goods	Cost of goods ₩1.2b (FY, 2025)	Cost of goods N/A	Cost of goods N/A	Cost of goods NT$2.1b (FY, 2025)	Cost of goods N/A
Gross profit	Gross profit ₩1.4b (FY, 2025)	Gross profit N/A	Gross profit N/A	Gross profit NT$2.2b (FY, 2025)	Gross profit N/A
Net income	Net income (₩3.3b) (FY, 2025)	Net income N/A	Net income N/A	Net income NT$1.5b (FY, 2025)	Net income N/A